Physician profile
Steven N Fine
NPI 1164498457
$259,423.10
in general payments reported to CMS, 2019-2025
19 companies · $90K in 2025
The $90K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $22K · 2021: $4,691 · 2022: $5,965 · 2023: $37K · 2024: $63K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168K · Travel and Lodging: $14K · Food and Beverage: $7,442 · Consulting Fee: $1,500 · Education: $37.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $167,574.36 |
| Travel and Lodging | $13,807.15 |
| Food and Beverage | $7,442.26 |
| Consulting Fee | $1,500.00 |
| Education | $37.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $96,468.89 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $66,712.11 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $48,662.03 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $36,478.68 | 2019-2025 | |
| Abbvie INC. | $7,905.09 | 2019-2025 | |
| Celgene Corporation | $2,121.59 | 2022-2024 | Zeposia |
| Genzyme Corporation | $352.31 | 2024-2025 | |
| Lilly USA, LLC | $143.28 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $125.79 | 2025 | Resolution 360 Clip |
| Celltrion USA INC. | $120.68 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $76.35 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $58.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.47 | 2023-2024 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $34.99 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $34.99 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $24.34 | 2024 | Resmetirom |
| Alnylam Pharmaceuticals INC. | $21.61 | 2025 | Givlaari |
| Ardelyx, INC. | $19.40 | 2024 | Ibsrela |
| Medtronic, INC. | $14.16 | 2023 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.